|
CN105294692A
|
|
Method for refining caffeine
|
|
CN104130259A
|
|
Ring-closure reaction method of caffeine intermediate 1,3-dimethyl-4-amino-5-formyl aminoureazine (FAU)
|
|
CN104003941A
|
|
Preparation method of caffeine intermediate N,N-1,3-dimethyl-4,5-diamido urazine
|
|
CN102875574A
|
|
Crystal form of ceftriaxone sodium and preparation method for crystal form
|
|
CN102718764A
|
|
Preparation method of 3-methyl-7-propylxanthine
|
|
CN102746232A
|
|
Preparation method of celecoxib impurity
|
|
CN102319223A
|
|
Esomeprazole freeze-dried preparation and preparation method thereof
|
|
CN102285970B
|
|
Esomeprazole compound, preparation method and pharmaceutical compoistion
|
|
CN102351853A
|
|
Azilsartan medoxomil compound, preparation method and medicinal composition thereof
|
|
CN102295619B
|
|
Febuxostat compound, preparation method and pharmaceutical composition thereof
|
|
CN102304088A
|
|
Ivabradine compound, preparation method and pharmaceutical composition thereof
|
|
CN102139051A
|
|
Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia
|
|
CN102174043A
|
|
Method for preparing linezolid intermediate
|
|
CN102040675A
|
|
Method for preparing hydroxypropyl-beta-cyclodextrin
|
|
CN101966156A
|
|
Azithromycin for suspension and preparation method thereof
|
|
CN101559228A
|
|
Pharmaceutical composition for treating chronic stable angina pectoris with hyperlipemia
|
|
CN101328174A
|
|
Method for preparing 3-(2-chloroethyl)-2-methyl-4H- naphthyridine[1,2-a]pyrimidine-4-ketone
|
|
CN101288648A
|
|
Easy-to-administrate oxiracetam granular formulation and preparation method
|
|
CN1883478A
|
|
Pharmaceutical composition for treating hypertension and cardiovascular disease
|
|
CN1864672A
|
|
A kind of solid dispersion of ambroxol hydrochloride and compositions thereof
|
